TriangleNCT03483103 · OUTCOME
Health-Related Quality of Life (HRQoL) Assessed by the FACT-Lym Subscale
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Scores on a scale
- Interval / dispersion
- Standard Deviation
- Time frame
- Baseline and Day 29
What was measured
The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) consists of the FACT-General scale and a 15-item lymphoma-specific additional concerns subscale (LYM). This scale addresses symptoms and functional limitations that are important to lymphoma patients. The LYM items are scored on a 0 ("Not at all") to 4 ("Very much") response scale. Items are aggregated to a single score on a 0-60 scale.
Analysis population: All participants who received at least one JCAR017 infusion who has an analyzable baseline scale and at least one post-baseline analyzable scale
Groups in this outcome
Lisocabtagene Maraleucel (JCAR017)
Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.
| Group | Source count |
|---|---|
| Lisocabtagene Maraleucel (JCAR017) | 49 |
Reported measurements
Baseline
| Group | Source count |
|---|---|
| Lisocabtagene Maraleucel (JCAR017) | 49 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Lisocabtagene Maraleucel (JCAR017) | 44.22 | 8.804 | Not reported | Not reported | Not reported |
Day 29
| Group | Source count |
|---|---|
| Lisocabtagene Maraleucel (JCAR017) | 42 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Lisocabtagene Maraleucel (JCAR017) | 48.71 | 6.447 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 8.804
- value
- 44.22
- denoms
- counts
- group Id
- OG000
- value
- 49
- units
- Participants
- title
- Baseline
- categories
- measurements
- group Id
- OG000
- spread
- 6.447
- value
- 48.71
- denoms
- counts
- group Id
- OG000
- value
- 42
- units
- Participants
- title
- Day 29
- denoms
- counts
- group Id
- OG000
- value
- 49
- units
- Participants
- description
- The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) consists of the FACT-General scale and a 15-item lymphoma-specific additional concerns subscale (LYM). This scale addresses symptoms and functional limitations that are important to lymphoma patients. The LYM items are scored on a 0 ("Not at all") to 4 ("Very much") response scale. Items are aggregated to a single score on a 0-60 scale.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.
- id
- OG000
- title
- Lisocabtagene Maraleucel (JCAR017)
- param Type
- MEAN
- population Description
- All participants who received at least one JCAR017 infusion who has an analyzable baseline scale and at least one post-baseline analyzable scale
- reporting Status
- POSTED
- time Frame
- Baseline and Day 29
- title
- Health-Related Quality of Life (HRQoL) Assessed by the FACT-Lym Subscale
- type
- SECONDARY
- unit Of Measure
- Scores on a scale
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice